Zevra Therapeutics Hits New 52-Week High of $14.27, Soars 190.95%

Zevra Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 14.27 on June 10, 2026. This achievement underscores the company's robust performance over the past year, with a remarkable 190.95% increase compared to the S&P 500's 20.34% gain during the same period. The company's financial metrics reflect its strong market position, highlighted by a price-to-earnings (P/E) ratio of 4.00 and a return on equity (ROE) of 89.05%. Zevra's market capitalization stands at USD 538 million, indicating its small-cap status. The stock has also demonstrated impressive growth in operating profit, which surged by 392.61%, alongside a net profit of USD 52.5 million, marking a 227.97% increase. Zevra Therapeutics has consistently delivered positive results, achieving outstanding performance over the last five consecutive quarters. With high institutional holdings at 82.89%, the company continues to show strong fundamentals, making it a noteworthy player in the market.